Osteopontin and Osteoprotegerin as Potential Biomarkers in Abdominal Aortic Aneurysm before and after Treatment

Table 1

Demographic data of control Group and AAA patients (overall, OR, and EVAR groups). All values of statistical significance in parenthesis are versus the control group.

	AAA patients			Control group; (𝑛=20)
	Overall (𝑛=74)	OR (𝑛=34)	EVAR (𝑛=40)
Arter. hypertension (%)	58 (78%) (NS)	29 (78%) (NS)	29 (73%) (NS)	17 (85%)
Dyslipidemia (%)	60 (81%) (NS)	28 (82%) (NS)	32 (80%) (NS)	13 (65%)
D. mellitus (%)	10 (14%) (NS)	4 (12%) (NS)	6 (15%) (NS)	3 (15%)
COPD (%)	8 (11%) (NS)	4 (12%) (NS)	4 (10%) (NS)	2 (10%)
Smoking (%)	50 (68%) (𝑃=0.037)	24 (71%) (𝑃=0.044)	26 (65%) (NS)	8 (40%)
Middle age (years) ± SD	65.3 ± 8 (NS)	64.2 ± 6 (NS)	66.5 ± 5 (NS)	64.7 ± 8
Male gender (%)	52 (68%) (NS)	23 (71%) (NS)	29 (73%) (NS)	13 (65%)

AAA: aortic abdominal aneurysm; OR: open repair; EVAR: endovascular aneurysm repair; COPD: chronic obstructive pulmonary disease.